Global MRSA Drugs Market to Reach US$ 5.0 Billion by 2032, Impelled by Increasing Incidences of Infections Associated with Methicillin-Resistant Staphylococcus Aureus (MRSA) Pathogens

April 04, 2023 | Healthcare

According to the latest report by IMARC Group, titled "MRSA Drugs Market by MRSA Type (Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)), Drug Class (Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, and Others), Disease Indication (Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections), Route of Administration (Oral Administration, Parenteral Administration), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032," the global MRSA drugs market reached a value of US$ 3.8 Billion in 2023. Methicillin-resistant staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many commonly used antibiotics, including methicillin, which is a type of penicillin. It is spread through contact with an infected person or contaminated surface and is most commonly associated with healthcare facilities, such as hospitals and nursing homes. MRSA infections can be difficult to treat and lead to serious health problems, particularly in individuals with weakened immune systems. There are several drugs available for the treatment of MRSA infections. Vancomycin is one of the most commonly used antibiotics for treating MRSA infections. Some of the other antibiotics used to treat MRSA include linezolid, daptomycin, ceftaroline, and tigecycline. The choice of antibiotic for MRSA infections depends on several factors, including the severity of the infection, the patient's medical history, and the susceptibility of the bacteria to different antibiotics. Sometimes, a combination of antibiotics may be used to treat the infection.

Global MRSA Drugs Market Trends:

The global market is majorly driven by the increasing incidences of MRSA infections. In line with this, the growing geriatric population and the development of new antibiotics for treating MRSA are significantly contributing to the market growth. Furthermore, the rising awareness about the importance of early diagnosis and treatment of MRSA infections is positively influencing the market. Apart from this, the escalating demand for effective treatments for MRSA infection is catalyzing the market. Moreover, the heavy investments in research and development of innovative anti-MRSA medication compounds and improved screening are expected to bolster the market. In addition, the key players are adopting inorganic expansion methods, such as mergers, acquisitions, and collaborations, which, in turn, are providing a boost to the market. Some other factors driving the market include the increasing prevalence of antibiotic resistant strains development, the rising number of cases of hospital-acquired infections (HAIs), rapid product innovations, easy availability of antibiotics, and growing healthcare expenditure. On account of the factors above, the market is anticipated to reach a value of US$ 5.0 Billion by 2032, exhibiting a CAGR of 3.11% during 2024-2032. 

Market Summary:

  • On the basis of the MRSA type, the market has been categorized into Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). Among these, Hospital-Acquired (HA-MRSA) represents the largest market segment. 
  • Based on the drug class, the market has been classified into lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. Currently, lipopeptides represent the largest segment.
  • Based on the disease indication, the market has been segmented into skin infections, bone and joint infections, bacteremia, and animal infections. At present, skin infections represent the largest segment.
  • Based on the route of administration, the market has been categorized into oral administration and parenteral administration, wherein parenteral administration holds for the biggest market segment.
  • Based on the distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. Presently, hospital pharmacies accounted for the largest market share.
  • On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and the Middle East and Africa. At present, North America holds the leading position in the market.
  • The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market. Some of the key players include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., and Pfizer Inc.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
MRSA Types Covered Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
Drug Classes Covered Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Others
Disease Indications Covered Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
Route of Administrations Covered Oral Administration, Parenteral Administration
Distribution Channels Covered Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global MRSA Drugs Market to Reach US$ 5.0 Billion by 2032, Impelled by Increasing Incidences of Infections Associated with Methicillin-Resistant Staphylococcus Aureus (MRSA) Pathogens
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More